NeuPath Health reduces loss in Q4 2023 while increasing revenues
Adjusted EBITDA attributable to shareholders of NeuPath Health for the quarter was C$0.8m, compared with C$0.7 a year ago.
Adjusted EBITDA attributable to shareholders of NeuPath Health for the quarter was C$0.8m, compared with C$0.7 a year ago.
Providers can utilise AI-powered insights from Nexus to aggregate patient diagnoses and tailor treatment approaches.
The healthcare industry continues to be a hotbed of patent innovation. Activity is driven by telemedicine, real-time diagnostics, smart hospitals...
HEALWELL seals agreements to offer preventative care AI tools in US
UK’s New Victoria Hospital to deploy MEDITECH’s EPR system
NHS to use AI software to reduce missed appointment rates
UCI Health adopts Abridge’s AI tool for clinical documentation